联特科技 reported revenue of ¥0.70B for the period ended 2026-06-30, +38.1% year on year. Net income was ¥0.01B, a 1.3% net margin on a 28.1% gross margin. The largest revenue line is 光模块及受托加工业务 at 99% of the total. Free cash flow for the period was ¥-0.23B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.70B | +38.1% |
| Gross profit | ¥0.20B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥0.01B | -73.1% |
| Gross margin | 28.1% | Net margin 1.3% |
| Revenue Q/Q | +126.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 光模块及受托加工业务 | ¥0.69B | 99.1% |
| 其他(补充) | ¥0.01B | 0.9% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.50B | 71.9% |
| R&D | ¥0.04B | 5.9% |
| SG&A | ¥0.07B | 10.4% |
| Tax & other | ¥-0.02B | -2.4% |
| Item | Amount |
|---|---|
| Total assets | ¥3.53B |
| Total liabilities | ¥1.90B |
| Shareholders' equity | ¥1.64B |
| Equity / assets | 46.3% |
| Operating cash flow | ¥-0.13B |
| Capital expenditure | ¥0.11B |
| Free cash flow | ¥-0.23B |
| Cash conversion (OCF / net income) | -2492% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
三元生物 ・ 华兰疫苗 ・ 中亦科技 ・ 联合化学 ・ 金杨精密 ・ 亨迪药业 ・ 联盛化学 ・ 观想科技 ・ 中汽股份 ・ 万凯新材 ・ 铜冠铜箔 ・ 华是科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies